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ABSTRACT
Hepatocellular carcinoma (HCC) is an important cause of cancer-related death 
worldwide. Ethnical disparity in overall survival has been demonstrated for HCC 
patients in the United States (U.S.). We aimed to evaluate the contributors to this 
survival disparity. The SEER database was used to identify HCC patients from 2004 to 
2012. Kaplan-Meier curves and Cox proportional hazard models were used to evaluate 
overall survival by ethnicity and the contributors to ethnical survival disparity. A 
total of 33 062 patients were included: 15 986 Non-Hispanic Whites, 6535 Hispanic 
Whites, 4842 African Americans, and 5699 Asians. Compared to Non-Hispanic Whites, 
African Americans had worse survival (HR, 1.18; 95%CI, 1.14–1.23), while Asians 
had a better  survival (HR, 0.85; 95%CI, 0.82–0.89), and Hispanic Whites had a 
similar survival (HR, 1.01; 95%CI, 0.97–1.05). Multivariate Cox analysis identified 
that tumor presentation- and treatment-related factors significantly contributed 
to the ethnical survival disparity. Especially, tumor size was the most important 
contributor (HR, 1.11; 95%CI, 1.07–1.16). There is no ethnical survival disparity 
in patients undergoing liver transplantation and sub-analysis of patients within the 
Milan criteria for liver transplantation demonstrated no significant survival disparity 
between African Americans and non-Hispanic Whites in transplantation adjustment 
analysis (HR, 1.23; 95%CI, 1.11–1.35 in non-adjustment analysis to HR, 1.05; 95%CI, 
0.95–1.15 after adjustment). Finally, no important contributor to the superior overall 
survival in Asians was identified. In conclusion, poor tumor presentation at diagnosis, 
limited benefit from resection and restricted utilization of liver transplantation are 
important contributors to poorer survival of African Americans with HCC.
INTRODUCTION
Hepatocellular Carcinoma (HCC) is the fifth most 
common malignancy and the second leading cause of 
cancer-related death worldwide [1]. Ethnicity has been 
demonstrated to be related to the prognosis of HCC 
patients in the United States (U.S.) [2–5]. In general, 
African American ethnicity is associated with the 
poorest overall survival rate; whereas Asian ethnicity 
is associated with the best overall survival [3–5]. To 
improve the quality of health care for HCC patients, it 
is important to identify the factors affecting this ethnical 
disparity in overall survival rates (OS), and to compare 
their impacts. 
Several factors associated with tumor presentation 
at time of diagnosis, type of surgical treatment, and 
socioeconomic status (SES), have previously been 
studied with regard to ethnic disparity in OS for HCC 
patients. Previous literature has reported that African 
American patients have a more advanced, and Asian 
patients a less advanced tumor stage at the moment of 
diagnosis, compared to non-Hispanic white patients 
[6, 7]. Obviously, more advanced disease at time of 
diagnosis may affect OS. However, access to curative 
treatment options may also play a role. African American 
patients have been demonstrated to have less surgical 
treatment (resection or liver transplantation (LT)) than non-
Hispanic white patients, and Asian patients are less likely to 
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have transplantation but more likely to have hepatectomy 
than non-Hispanic white patients [6–8]. However, it should 
be noted that there have been inconsistent reports about 
treatment effects. Mathur et al [9] reported that after tumor 
ablation and hepatic resection, African American and 
Hispanic patients had the worst survival. Asian patients had 
better survival than white patients after ablation and similar 
survival after hepatectomy. After liver transplantation, there 
was no significant difference in survival by race/ethnicity 
[9]. On the other hand, several other studies have reported 
that African American patients have worse OS after liver 
transplantation than non-Hispanic white patients [3, 10]. 
Finally, socioeconomic status (SES) could be the potential 
driving factor for ethnical survival disparity as it can affect 
healthcare-utilization (early detection, treatment, and post-
treatment quality of life) in cancer patients [11]. However, 
several studies have found that SES does not explain ethnic 
disparity in OS for HCC patients [11, 12]. 
Inconsistencies in study results might be due to 
differences between the populations and study designs. 
Nevertheless, there are many socioeconomic and tumor- 
and treatment-related factors that may impact racial 
disparity in survival of HCC patients more or less, and 
as far as we know their influence on OS has not been 
compared [4]. In this study we describe the relative 
contributions of these factors to the ethnical disparity 
in OS for HCC patients, using The Surveillance, 
Epidemiology, and End Results (SEER) database.   
RESULTS
Population 
Based on inclusion criteria, this study included a total 
of 33 062 patients who were diagnosed with HCC from 
2004 to 2012 (Supplementary Figure 1). The population 
characteristics are summarized in Table 1. Among them, 15 
986 (48%) were Non-Hispanic Whites, 6535 (20%) were 
Hispanic Whites, 4842 (15%) were African Americans, 
and 5699 (17%) were  Asians (Asian or Pacific Islander). 
Although not statistically significant, in comparison to 
other ethnicities, Asians had a higher average age (mean 
age: 63 years, IQR:55–73) than Non-Hispanic Whites 
(mean age: 62; IQR: 55–72) and African Americans (mean 
age: 59; IQR: 54–64). Additionally, African Americans 
were more likely to be diagnosed with large tumor (tumor 
size > 5cm) than Non-Hispanic Whites, and vice versa. For 
example, among African Americans 38% had large tumor 
and 17% had small tumor; among Non-Hispanic Whites 
34% had large tumor and 22% had small tumor (p < .0001). 
Ethnical disparity in overall survival in overall 
HCC population 
Figure 1 displays the overall survival (OS) rates 
among different ethnical populations. The median survival 
was 8 months (95%CI: 7.6–8.4), 9 months (95%CI: 
8.4–9.6), 6 months (95%CI:5.5–6.5), and 13 months 
(95%CI: 12.0–14.0) for Non-Hispanic White, Hispanic 
White, African American, and Asian patients, respectively. 
1-year and 3-year survival rates were 44% and 24%, 45% 
and 23%, 38% and 18%, and 51% and 31% for Non-
Hispanic White, Hispanic White, African American, and 
Asian patients, respectively. Therefore, Hispanic White 
and Non-Hispanic White patients had similar survival 
rates. Asian patients displayed the best OS, and African 
American patients had the poorest OS. Specifically, there 
was significant “negative” survival disparity between 
African American and Non-Hispanic White patients 
(P < .0001), and “positive” survival disparity between 
Asian and White patients (P < .0001). 
To determine the importance of several demographic-, 
tumor- and treatment-related factors for ethnical survival 
disparity, we performed multivariate analyses, and then 
observed the change of hazard ratios (HRs). Figure 2 
shows a forest plot presenting results from multivariate 
Cox models for all ethnical groups in the overall population 
(reference: Non-Hispanic White). No significant difference 
was observed between Hispanic White and Non-Hispanic 
White both in univariate analysis (HR, 1.01; 95%CI, 
0.97–1.05) and multivariate analysis (HR, 0.98; 95%CI, 
0.95–1.02). However, with respect to African American 
patients, we noticed some remarkable changes in survival 
disparity in Cox models. The initial survival disparity 
between African American and Non-Hispanic White (HR, 
1.18; 95%CI, 1.14–1.23) did not change much when we 
adjusted demography-related variables. However, it was 
affected by tumor size (HR, 1.11; 95%CI, 1.07–1.16), 
which indicated that the increased occurrence of  large 
tumor in African Americans was associated with their 
poor survival. The other tumor-related variables that 
we studied did not significantly change the survival 
disparity any further. After additional adjustment for 
treatment-related factors, the significant survival disparity 
between African Americans and Non-Hispanic Whites 
became non-significant (HR, 1.03; 95%CI, 0.99–1.07). 
Therefore, we conclude that tumor size and treatment 
contributed largely to the survival disparity between 
African American and Non-Hispanic White patients. When 
comparing Non-Hispanic Whites to Asian patients, the 
latter population displayed a significantly better survival 
(HR, 0.85; 95%CI, 0.82–0.89), which remained constant 
from univariate analysis (HR, 0.85; 95%CI, 0.82–0.89) 
to multivariate analysis (HR, 0.86; 95%CI, 0.83–0.90). In 
other words, we did not identify the contributors to superior 
survival in Asian patients.  
Since, for a large group of patients fibrosis scores 
were unavailable in the full SEER dataset, which may 
present a bias with respect to the survival data, we further 
analyzed a subset of patients for which this fibrosis score 
was available (n = 7070, characteristics in Supplementary 
Table 1). Supplementary Figure 3 demonstrates that 
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Table 1: Characteristics of all patients by ethnicity
Characteristics Total 
Ethnicity     
Non-Hispanic White Hispanic White African American Asian P Value
Patients
 No. % 33 062 15 986  (48) 6535  (20) 4842  (15) 5699  (17)
Age      < .0001a
 Mean [SD],y 63 [12] 63 [11] 62 [12] 60 [10] 63 [13]
 Median [IQR],y 61 [55–71] 62 [55–72] 60 [53–70] 59 [54–64] 63 [55–73]
Gender  (%)      < .0001b
 Male 25 728  (78) 12 698  (79) 5061  (77) 3779  (78) 4190  (74)
 Female 7334  (22) 3288  (21) 1474  (23) 1063  (22) 1509  (27)
Marital status  (%)      < .0001a
 Married 16937  (51) 8151  (51) 3285  (50) 1607  (33) 3894  (68)
 Unmarried 14775  (45) 7158  (45) 3003  (46) 2999  (62) 1615  (28)
 Unknown 1350  (4) 677  (4) 247  (4) 236  (5) 190  (3)
Education  (%)c      < .0001b
 Mean [SD] 16 [6] 15 [6] 19 [6] 16 [5] 16 [5]
 Median [IQR] 15 [12–22 ] 14 [11–20] 20 [14–23] 15 [12–18] 14 [12–23]
Poverty  (%)      < .0001a
 Mean [SD] 16 [5] 15 [5] 17 [4] 18 [6] 14 [4]
 Median [IQR] 16 [12–18] 14 [12–18] 18 [13–18] 18 [13–23] 13 [10–18]
Income  (%)      < .0001a
 Mean [SD] 59619 [14401] 58 600 [14690] 59478 [12533] 53924 [13423] 67477 [13132]
 Median [IQR] 55910 [50588–69710 ] 56490  [48260–66520] 55910 [54090–62960] 55060 [41180–61260] 67180 [55910–75600]
Residence  (%)      < .0001b
 Rural 2592 (8) 1957 (12) 255 (4) 265 (5) 115 (2)
 Urban 30470 (92) 14029 (88) 6280 (96) 4577 (95) 5584 (98)
Lesion number  (%)      .002b
 Single 32015 (97) 15438 (97) 6373 (98) 4697 (97) 5507 (97)
 Multiple 1047 (3) 548 (3) 162 (2) 145 (3) 192 (3)
Grade  (%)      < .0001b
 Well differentiated 4325 (13) 2209 (14) 883 (14) 598 (12) 635 (11)
 Moderately differentiated 5377 (16) 2664 (17) 896 (14) 797 (16) 1020 (18)
 Poorly differentiated 2854 (9) 1358 (8) 466 (7) 438 (9) 592 (10)
 Undifferentiated 281 (1) 140 (1) 43 (1) 39 (1) 59 (1)
 Unknown 20225 (61) 9615 (60) 4247 (65) 2970 (61) 3393 (60)
Stage  (%)      < .0001b
 Localized 16143 (49) 7822 (49) 3304 (51) 2175 (45) 2842 (50)
 Regional 9618 (29) 4573 (29) 1849 (28) 1473 (30) 1723 (30)
 Distant 5201 (16) 2466 (15) 984 (15) 906 (19) 845 (15)
 Unstaged 2100 (6) 1125 (7) 398 (6) 288 (6) 289 (5)
Tumor size  (cm),%      < .0001b
 < 3 6693 (20) 3499 (22) 1335 (20) 808 (17) 1051 (18)
 3–5 7519 (23) 3613 (23) 1601 (24) 1030 (21) 1275 (22)
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this subpopulation African Americans also had a poorer 
survival than Non-Hispanic Whites (HR, 1.19; 95%CI, 
1.08–1.31). This survival disparity in multivariate analysis 
was again affected by tumor size; the factor large tumor 
size was associated with poor survival (HR, 1.10, 95%CI, 
1.00–1.22). 
Ethnical disparity in overall survival in patients 
stratified by treatment 
We further explored the survival patterns among 
ethnicities in subgroups stratified by treatment: patients 
treated with tumor destruction (radiofrequent ablation / 
percutaneous ethanol injection (PEI) etc.) (9% of total), 
those that had surgical resection (9% of total), and those 
that have had liver transplantation (6% of total) (Table 1). 
As for the patients who underwent tumor destruction, both 
African Americans and Hispanic Whites showed non-
significant survival difference compared to Non-Hispanic 
Whites. Asians had a much higher survival rate than Non-
Hispanic Whites (HR, 0.71; 95%CI, 0.61–0.82) and no 
specific reason was found for this disparity (Figure 3A). 
For patients receiving surgical resection, we found 
significantly lower survival rates in Hispanic Whites (HR, 
1.20; 95%CI, 1.00–1.42) and African Americans (HR, 
1.27; 95%CI, 1.08–1.50) than in Non-Hispanic Whites. 
Demographic and tumor-related factors negatively 
influenced survival in Hispanic Whites but for African 
Americans no such contribution could be identified 
among the various Cox models. Of interest, after surgical 
 > 5 12184 (37) 5497 (34) 2370 (36) 1847 (38) 2470 (43)
 Unknown 6666 (20) 3377 (21) 1229 (19) 1157 (24) 903 (16)
Lymph node involvement 
(%)
     < .0001b
 No lymph node 25833 (78) 12380 (77) 5091 (78) 3753 (78) 4609 (81)
 Lymph node 2272 (7) 1239 (8) 351 (5) 401 (8) 281 (5)
 Unknown 4957 (15) 2367 (15) 1093 (17) 688 (14) 809 (14)
Vascular Invasion  (%)      < .0001b
 No Vascular Invasion 16749 (51) 8187 (51) 3412 (52) 2297 (47) 2853 (50)
 Vascular Invasion 13467 (41) 6269 (39) 2569 (39) 2137 (44) 2492 (44)
 Unknown 2846 (9) 1530 (10) 554 (8) 408 (8) 354 (6)
Metastatic status  (%)      < .0001b
 No metastasis 25038 (76) 12119 (76) 4937 (76) 3579 (74) 4403 (77)
 Metastasis 5154 (16) 2469 (15) 989 (15) 882 (18) 814 (14)
 Unknown 2870 (9) 1398 (9) 609 (9) 381 (8) 482 (8)
AFPd  (%)      < .0001b
 Positive 19366 (59) 8672 (54) 3928 (60) 3221 (67) 3545 (62)
 Negative 5705 (17) 3002 (19) 1186 (18) 546 (11) 971 (17)
 Borderline 74 (0) 48 (0) 8 (0) 10 (0) 8 (0)
 Unknown 7917 (24) 4264 (27) 1413 (22) 1065 (22) 1175 (21)
Fibrosis  (%)      < .0001b
 None to moderate fibrosis 1622 (5) 723 (5) 236 (4) 220 (5) 443 (8)
 Severe fibrosis or cirrhosis 5448 (16) 2678 (17) 1209 (19) 709 (15) 852 (15)
 Unknown 25992 (79) 12585 (79) 5090 (78) 3913 (81) 4404 (77)
Treatment  (%)      < .0001b
 None 24646 (75) 11672 (73) 5178 (79) 3850 (80) 3946 (69)
 Tumor destruction 3102 (9) 1544 (10) 596 (9) 368 (8) 594 (10)
 Surgical resection 3002 (9) 1364 (9) 349 (5) 406 (8) 883 (15)
 Liver transplantation 2016 (6) 1221 (8) 374 (6) 178 (4) 243 (4)
 Unknown 296 (1) 185 (1) 38 (1) 40 (1) 33 (1)  
 a one-way ANOVA test.
  b Pearson Chi-Square.
 c Indicates the percentage of adults aged ≥ 25 years who had < 12 years of education.
 d AFP positive indicates AFP > 15 ng/ml. 
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Table 2: Characteristics of the patients within Milan criteria
Characteristics Total 
Ethnicity    
Non-Hispanic White Hispanic White African American Asian P Value
Patients
 No. % 8 524 4290  (50) 1779  (21) 1056  (12) 1399  (16)
Age      < .0001
 Mean [SD],y 61 [10] 61 [10] 60 [10] 60 [9] 64 [11]
 Median [IQR],y 60 [54–68] 60 [55–67] 59 [53–67] 59 [55–64] 63 [55–72]
Gender (%)      < .0001
 Male 6425  (75) 3380 (79) 1319 (74) 791 (75) 935 (67)
 Female 2099  (25) 910 (21) 460 (26) 265 (25) 464 (33)
Marital status (%)      < .0001
 Married 4471 (52) 2223 (52) 896 (50) 379 (36) 973 (70)
 Unmarried 3732 (44) 1893 (44) 825 (46) 625 (59) 389 (28)
 Unknown 321 (4) 174 (4) 58 (3) 52 (5) 37 (3)
Education      < .0001
 Mean [SD] 16 [6] 15 [6] 19 [6] 16 [5] 16 [5]
 Median [IQR] 15 [12–22] 14 [11–19] 18 [14–23] 15 [12–16] 14 [13–20]
Poverty      < .0001
 Mean [SD] 15 [5] 15 [5] 16 [5] 18 [6] 14 [4]
 Median [IQR] 15 [12–18] 14 [12–18] 18[13–18] 18 [13–21] 13 [10–18]
Income      < .0001
 Mean [SD] 60176 [14217] 58775 [14214] 60168 [12703] 54675 [13422] 68633 [13069]
 Median [IQR] 56530 [51380–72110] 56530 [48510–65590] 55910 [54090–63360] 55060 [41180–62000] 72110 [55910–75600]
Residence (%)      < .0001
 Rural 585 (7) 468 (11) 60 (3) 41 (4) 16 (1)
 Urban 7939 (93) 3822 (89) 1719 (97) 1015 (96) 1383 (99)
Lesion number (%)      .100
 Single 8309 (97) 4170 (97) 1747 (98) 1033 (98) 1359 (97)
 Multiple 215 (3) 120 (3) 32 (2) 23 (2) 40 (3)
Grade (%)      < .0001
 Well differentiated 1457 (17) 766 (18) 293 (16) 176 (17) 222 (16)
 Moderately 
differentiated
1582 (19) 807 (19) 270 (15) 213 (20) 292 (21)
 Poorly differentiated 461 (5) 230 (5) 79 (4) 49 (5) 103 (7)
 Undifferentiated 39 (0) 20 (0) 7 (0) 3 (0) 9 (1)
 Unknown 4985 (58) 2467 (58) 1130 (64) 615 (58) 773 (55)
Stage (%)      .013
 Localized 8228 (97) 4128 (96) 1728 (97) 1009 (96) 1363 (97)
 Regional 295 (3) 162 (4) 51 (3) 46 (4) 36 (3)
 Distant 1 (0) 0 (0) 0 (0) 1 (0) 0 (0)
Tumor size (cm),%      < .001
 < 3 4465 (52) 2348 (55) 901 (51) 524 (50) 692 (49)
 3–5 4059 (48) 1942 (45) 878 (49) 532 (50) 707 (51)
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resection Asians did not have significantly higher survival 
rates than Non-Hispanic Whites (Figure 3B). Interestingly, 
no significant ethnical difference in survival was detected 
in patients after liver transplantation (Figure 3C). 
Ethnical survival disparity in patients eligible for 
liver transplantation
To further explore the impact of liver transplantation 
on ethnical survival disparity, we performed survival 
analyses in a subgroup of patients who met  the Milan 
criteria for liver transplantation (1 nodule ≤ 5 cm and 
max 3 nodules ≤ 3cm and no signs of vascular invasion/
extrahepatic spread). Table 2 describes the characteristics 
for those patients. The patients receiving liver 
transplantation accounted for 15% of total patients “within 
Milan”; 19% of Non-Hispanic Whites (n = 802), 11% of 
African Americans (n = 111), 13% of Hispanic Whites 
(n = 232), and 10% of Asians (n = 137) (P < .0001). The 
survival rates are displayed in Figure 4. Compared to 
Non-Hispanic Whites, Hispanic White patients exhibited 
a poorer survival (HR, 1.12; 95%CI, 1.03–1.22), which 
was improved when adjusting for tumor-related factors 
but became not significant after adjusting for liver 
transplantation. Also, African American patients displayed 
a poorer survival (HR, 1.23; 95%CI, 1.11–1.35), and their 
outcome was improved when adjusting tumor-related 
variables. But especially when transplantation status 
was adjusted, the survival discrepancy disappeared (HR, 
1.05; 95%CI, 0.95–1.15). Finally, the superior survival 
remained constant for Asian patients from crude analysis 
to adjustment analyses. 
DISCUSSION
Since HCC related mortality continues to increase 
in the US, the ethnical disparities in overall survival has 
attracted attention [13]. Many efforts have been devoted 
to exploring the reasons behind this phenomenon [4, 14] 
for a better understanding of its contributors, which shall 
help us to determine  which interventions could reduce 
this disparity. 
We have confirmed the ethnical survival disparity 
in overall survival that has previously been reported by 
others [3–6, 9]. We demonstrated how tumor-related and 
treatment-related factors contribute strongly to survival 
Lymph node involvement 
(%)
     
.001
 No lymph node 8173 (96) 4099 (96) 1706 (96) 1004 (95) 1364 (97)
 Lymph node 149 (2) 92 (2) 19 (1) 25 (2) 13 (1)
 Unknown 202 (2) 99 (2) 54 (3) 27 (3) 22 (2)
Vascular Invasion (%)      NA
 No Vascular Invasion 8524 (100) 4290 (100) 1779  (100) 1056  (100) 1399  (100)
Metastatic status (%)      NA
 No metastasis 8524 (100) 4290 (100) 1779  (100) 1056  (100) 1399  (100)
AFP (%)      < .0001
 Positive 4629 (54) 2126 (50) 985 (55) 682 (65) 836 (60)
 Negative 2176 (26) 1196 (28) 482 (27) 175 (17) 323 (23)
 Borderline 21 (0) 15 (0) 2 (0) 2 (0) 2 (0)
 Unknown 1698 (20) 953 (22) 310 (17) 197 (19) 238 (17)
Fibrosis (%)      < .0001
 None to moderate 
fibrosis
523 (6) 253 (6) 59 (3) 68 (6) 143 (10)
 Severe fibrosis or 
cirrhosis
2139 (25) 1081 (25) 469 (26) 261 (25) 328 (23)
 Unknown 5862 (69) 2956 (69) 1251 (70) 727 (69) 928 (66)
Therapy (%)      < .0001
 None 4478 (53) 2167 (51) 1103 (62) 604 (57) 604 (43)
 Tumor destruction 1746 (20) 864 (20) 320 (18) 202 (19) 360 (26)
 Surgical resection 980 (11) 432 (10) 120 (7) 133 (13) 295 (21)
 Liver transplantation 1282 (15) 802 (19) 232 (13) 111 (11) 137 (10)
 Unknown 38 (0) 25 (1) 4 (0) 6 (1) 3 (0)  
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Figure 1: The Kaplan-Meier survival curves showing ethnical survival disparities.  
Figure 2: Forest plot presenting the estimated HR’s of ethnicity on overall survival  from multivariate Cox models for 
all ethnical groups (reference: Non-Hispanic White). The first HR is the crude effect followed by HR after adjustment entering 
covariates in a forward stepwise manner (LR): age, marriage, gender, income, education, tumor size, stage, grade, AFP, number of lesion, 
metastatic status, fibrosis, lymph node status, vascular invasion, and treatment. Block 1 included race, block 2 included age, gender, marital 
status, education, income, poverty, residence, block 3 included grade, stage, number of lesion, tumor size, lymph node status, vascular 
invasion, metastatic status, AFP, and fibrosis, and block 4 included treatment. 
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disparity between African American and Non-Hispanic 
White patients.  
As demonstrated in previous studies, compared to 
non-Hispanic Whites we found a poor survival in African 
Americans and a good survival in Asian patients [4, 7, 
9, 12, 15, 16]. Our results demonstrate that increased 
presence of large tumor size was associated with poor 
survival in African Americans.  Tumor size is considered 
as an important prognostic determinant in several HCC 
staging systems such as the TNM classification [17], 
the Barcelona Clinic Liver Cancer (BCLC) staging 
system [18], and the Hong Kong Liver Cancer (HKLC) 
classification [19]. Although previous studies have 
reported the significant differences in tumor size in HCC 
patients stratified by race and proposed it as a predictor of 
prognosis for HCC patients [4, 7, 9, 12, 15, 16], our study 
has demonstrated that tumor presentation indeed is the 
dominant contributor to the poor OS of African Americans. 
Such a clear dominant factor could not be demonstrated 
for Hispanic-Whites and Asians. In the former population 
demographic factors contributed to OS to some extent, 
but again presentation-related factors were shown to 
Figure 3: Forest plot presenting the estimated HR’s of ethnicity on overall survival from multivariate Cox models for 
all ethnical groups stratified by treatment (reference: Non-Hispanic White). Forward stepwise method was used to study the 
changes of HR of ethnicity after entering the following covariates: In the stratum (A) Destruction: race, age, education, stage, tumor size, 
number of lesion, AFP, grade, and vascular invasion. In the stratum (B) Resection: race, gender, age, marriage, stage, grade, tumor size, 
number of lesion, AFP, fibrosis, and vascular invasion. And in the stratum (C) Transplantation: race, vascular invasion, stage, and tumor 
size.   
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be the dominant contributors. Stage of liver disease as 
represented by fibrosis score did not significantly impact 
the observed survival disparities, as in a sub-analysis of 
patients of which these data were available tumor size 
remained a major confounder. 
Consistent with previously studies, we found 
superior OS in Asians. Marital status affected HRs to some 
extent, and in our population Asians showed the highest 
percentage of marriage: up to 70% (P < .0001). Multiple 
studies have shown that being married is associated with 
more favorable survival for various cancer types [20–23] 
and this also appears to be the case in Asian HCC patients. 
Treatment related factors also contributed to ethnical 
survival differences. As reported by others [9] African 
Americans displayed the poorest response to resection. 
We cannot explain this finding based on our data. African 
Americans were previously reported to have a longer 
waiting time period before surgery [12], which may affect 
the severity of their liver disease and consequently the 
chance on complications after surgery. However, this 
information was not available for us to study. 
We speculate that there is an impact of the etiology 
of liver disease on both the observed overall survival 
disparities and the discrepancies found in relation to 
treatment modality. The cause of liver disease in the 
majority of Asian HCC patients is chronic HBV infection; 
whereas in African Americans and non-Hispanic Whites 
chronic HCV infection, non-alcoholic fatty liver disease 
(NAFLD) and alcohol abuse are more common [24]. 
HBV infection is well manageable whereas HCV infection 
(before the DAA era) would have been progressive after 
resection or destruction. NAFLD is associated with obesity 
and diabetes and both can potentially lead to serious 
comorbidity [25], and alcohol abuse may have continued 
or recurred. Differences in etiology of underlying liver 
disease or (their impact on) comorbidity as contributors 
to the observed survival disparities after resection could 
not be studied since these data were not present in our 
database.
Interestingly, no significant ethnical survival 
difference was observed after liver transplantation. These 
results do not match the study by Ananthakrishnan et 
al. [10], who reported that African American patients 
benefitted less from transplantation than Non-Hispanic 
Whites, using a United Network for Organ Sharing 
database [10]. However, our findings are in line with the 
data reported by Mathur et al [9], who also studied the 
SEER-database [9]. Therefore, these inconsistencies may 
be due to different patient populations analyzed. Although, 
Artinyan et al also used SEER data to report poorer 
survival after transplantation for African Americans [3], 
we believe that the population described in this particular 
study which included patients with diagnostic year as 
early as 1973 until 2004, is significantly different from 
our study population since implementation of the Milan 
criteria for liver transplantation in clinical practice only 
occurred after year of 1996 [26]. Therefore, differences in 
eligibility criteria for liver transplantation may explain the 
differences in results between our and their study. 
We next explored a potential role for receiving 
liver transplantation on ethnical survival disparity. This 
issue has been discussed extensively over the years 
[6–8]. Several studies have demonstrated limited access 
to transplantation for African American patients, and 
Figure 4: Forest plot presenting the estimated HR’s of ethnicity on overall survival from multivariate Cox models for 
all ethnical groups who met Milan criteria (reference: Non-Hispanic white). The first HR is the crude effect followed by HR 
after adjustment entering covariates in a forward stepwise manner (LR): age, marriage, gender, education, grade, tumor size, AFP, fibrosis, 
lymph node status, number of lesion, and transplantation. Block 1 included race, block 2 included age, gender, marital status, education, 
income, poverty, residence, block 3 included grade, stage, number of lesion, tumor size, lymph node status, vascular invasion, metastatic 
status, AFP, and fibrosis, and block 4 included treatment.
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indeed also in our study African Americans eligible for 
liver transplantation received this potentially curative 
treatment less frequently than non-Hispanic Whites. But 
as also reported before, so did Asian HCC patients [8–10, 
12, 27–30]. Some studies have suggested that disparity in 
receiving transplantation may have contributed to ethnical 
disparity in survival [4, 9]. To determine the impact of 
undergoing liver transplantation on ethnical differences in 
survival, we analyzed the subgroup of patients who met 
the Milan criteria. Compared to Non-Hispanic Whites, 
Hispanic White and African American patients exhibited 
a poorer survival, and indeed their survival discrepancy 
disappeared after adjusting transplantation status. Asians 
“within Milan” on the other hand have better outcome 
which is unaffected by the factor liver transplantation. 
These patients have been shown to receive resection more 
often than liver transplantation and more often than any 
other race [7], and this is confirmed in our study. Since 
most of the Asian cases are likely HBV related [24] and 
may therefore have relatively preserved underlying liver 
function, more Asians can tolerate liver resection. It 
probably explains the small impact of transplantation on 
their survival. Of note, we could not identify a significant 
contributing role for socioeconomic or demographic 
factors to the ethnic survival discrepancy in this subgroup, 
suggesting that these factors may not determine access to 
transplantation. Indeed, whether or not to transplant is a 
complex decision making process that involves evaluation 
of etiology of liver disease, comorbidity, social context 
etc. and as said, these factors could not all be analyzed in 
our study. 
Our work has some limitations. Firstly, since our 
study is retrospective in nature, it holds the known biases 
associated with this type of study. Secondly, as mentioned 
the level of clinical detail available to us does not capture 
significant details that may affect the use of surgical 
therapy or survival, such as medical comorbidities, 
presence of chronic liver disease and its etiology, and 
information on the details of all treatments received. 
Thirdly, the county-level socioeconomic data may not 
fully capture the economic, educational, and social 
factors for individual patients. Lack of social support, 
density of specialists within a region, hospital volume, 
distance to care, and other unmeasured confounders may 
have influenced access to therapies. Lastly, the effects of 
sorafenib or TACE on ethnical survival difference could 
not be studied since SEER has no specific coding for these 
treatment modalities. Nevertheless, to our knowledge, 
our analysis represents the most comprehensive study on 
ethnic differences in survival for HCC patients in the US. 
In conclusion, we have confirmed the ethnical 
disparities in overall survival of HCC patients in the US. 
Poor tumor-presentation at diagnosis, poor response to 
resection, and limited utilization of transplantation all play 
essential roles in the poorer survival of African Americans 
compared to other races. Asian patients have superior 
survival, but after liver transplantation ethnic disparity in 
survival is absent.   
MATERIALS AND METHODS
Patients selection
This study was performed using data from the 
Surveillance, Epidemiology, and End Results (SEER) 
Program (www.seer.cancer.gov) SEER*Stat Database 
(version 8.2.1). The procedure for selecting the patients 
for the cohort is shown in Supplementary Figure 1. Briefly, 
these patients were diagnosed between 2004 and 2012. 
We included the following ethnicities: Non-Hispanic 
White, Hispanic White, African American, and Asian 
(Asian/Pacific Islander). Among the Asian population in 
this study, 41.4% (2360/5699) were East Asians, 3.8% 
(219/5699) were South Asians, 39.2% (2233/5699) 
were Southeast Asians, and 15.6% were other Asians 
(887/5699). Native American (American Indian/Alska 
native) were excluded from our study. SEER Vital status 
recode (study cutoff used) variable was used to define 
the status of patients after the last follow-up date: death 
and alive. The survival time months variable, starting 
from diagnosis to last follow-up, was used for extracting 
information on patients’ survival time. The follow-up 
cut-off date was December 31, 2012. Among the overall 
population, we selected patients within Milan criteria: one 
lesion ≤ 5 cm or up to 3 lesions each with diameter ≤ 3 cm; 
no extra-hepatic involvement; and no vascular invasion. 
Definition
SEER Staging (also called Summary Staging) was 
used to define HCC stage: localized, regional, and distant. 
SEER Staging is the most basic way of categorizing 
how far a cancer has spread from its point of origin, as 
it combines the most precise clinical and pathological 
documentation of the extent of disease (http://training.
seer.cancer.gov/ss2k/staging/). The detailed SEER Staging 
for HCC is documented in the “SEER Summary Staging 
Manual”. For example, localized HCC indicates the cancer 
confined to one lobe with or without vascular invasion, or 
multiple nodules/tumors confined to one lobe. 
HCC therapies were categorized into groups based 
on data available in SEER database: none, local tumor 
destruction, surgical resection, and liver transplantation 
(LT). None indicated: without any intervention such 
as local tumor destruction, surgical resection, or liver 
transplantation. Local tumor destruction included: 
photodynamic therapy (PDT), electrocautery, cryosurgery, 
laser, PEI, heat-radio-frequency ablation (RFA). Since 
SEER has no specific coding for chemotherapy (sorafenib) 
or chemoembolization (TACE), they were not specified 
as such in SEER database. Resection included wedge, 
segmental resection, and lobectomy. “Unknown” means 
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uncertainty about whether surgery was performed or what 
type of surgery was done.     
The following SES related variables were included: 
education (the percentage of adults aged ≥ 25 years who 
< 12 years of education), poverty (the percentage of 
individuals living below the poverty line), and income 
(median annual household income). These variables were 
used as continuous variables in this study. According to 
the definitions of Country Attributes in SEER data, the 
higher values of the variables of education and poverty 




Descriptive statistics were reported as both mean 
with standardized deviation (SD), and median with 
interquartile range (IQR) for continuous variables, and 
whole number with percentage for categorical variables. 
One-way ANOVA was used to compare groups for 
continuous variables. Pearson Chi-Square was used for 
comparing groups for categorical variables. Crude (non-
adjustment) survival analysis (Kaplan-Meier curve) was 
first used to display the overall observed ethnical survival 
differences. Hazard ratio (HRs) and 95% CIs were 
calculated to evaluate the prognostic power of variables 
in survival. The included variables were divided into three 
categories:1) demographic variables, including race, age, 
SEER site, gender, marital status, education, income, 
poverty, residence; 2) presentation-related variables, 
including grade, stage, number of lesion, tumor size, 
lymph node involvement (yes or no), vascular invasion 
(yes or no), metastatic status (yes or no), AFP (Alpha-
fetoprotein), and fibrosis degree (none to moderate 
fibrosis; several fibrosis or cirrhosis); and 3) treatment-
related variables, including treatment presenting with 
categories — no treatment, tumor destruction, resection, 
and transplantation. For the procedure of multivariate 
cox model, race was entered as block 1, the remaining 
demographic variables were entered as block 2 (including 
age, gender, marital status, education, income, poverty, 
residence), presentation-related variables were entered 
as block 3 (including tumor size, stage, grade, number 
of lesion, lymph node status, vascular invasion status, 
metastatic status, AFP, and fibrosis staging), and finally 
treatment-related variable was entered as block 4. All 
analysis were stratified on SEER site to adjust for any 
heterogeneity between sites. Regarding block 2 and 3, 
the covariates were entered in a forward stepwise manner 
using the Likelihood Ratio test ( LR ) to describe their 
impact on survival. The changes in the HR’s of African 
Americans, Hispanic White and Asian versus Non-
Hispanic White after the stepwise adjustment of the 
covariates are shown in forest plots. There were some 
missing values for several categorical variables in our 
study. As we did not find any significant differences 
from the analysis of all cases and the cases with known 
values, we treated the missing values (with “unknown” 
label shown in Tables 1–2) as a separate subcategory. Data 
preparation and forest plot were done in R (version 3.3.1). 
Statistical analyses was performed in SPSS (version 21); 
syntax shown in Supplementary Figure 2. P < .05 (two 
tailed sides) was considered as significant. 
ACKNOWLEDGMENTS
We thank the Website Support Team and the Data 
Quality Team from SEER at the National Cancer Institute 
for providing helps in formulating a specific case-listing 
session, in extracting exact variable information from 
SEER*Stat database, and the suggestions on the survival 
analysis of SEER data.  
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING
Dr. Li received a graduate scholarship from the 
China Scholarship Council (No. 201307720054). Dr. Pan 
received a fellowship award from the Daniel den Hoed 
Foundation and a VENI grant from the Netherlands 
Organization for Scientific Research (No. 916-13-032). 
Authorsʼ contributions
J.L. and D.S. designed the study. J.L., B.H., and 
D.S. analyzed and interpreted the data. J.L. and D.S. wrote 
the manuscript, and all contributed to and approved the 
final version of the manuscript.
REFERENCES
1. Mittal S, El-Serag HB. Epidemiology of hepatocellular 
carcinoma: consider the population. J Clin Gastroenterol. 
2013; 47:S2–6.
2. Wang S, Sun H, Xie Z, Li J, Hong G, Li D, Mallampati S, 
Zhou X, Zhou C, Zhang H, Cheng Z, Shan H, Ma H. 
Improved survival of patients with hepatocellular carcinoma 
and disparities by age, race, and socioeconomic status by 
decade, 1983–2012. Oncotarget. 2016; 7:59820–59833. doi: 
10.18632/oncotarget.10930.
3. Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, 
Bhatia S, Wagman LD, Nissen N, Colquhoun SD, Kim J. 
Race, ethnicity, and socioeconomic status influence the 
survival of patients with hepatocellular carcinoma in the 
United States. Cancer. 2010; 116:1367–1377.
4. Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Racial 
disparities in treatment and survival of patients with 
hepatocellular carcinoma in the United States. Hepatobiliary 
Surg Nutr. 2016; 5:43–52.
Oncotarget15204www.impactjournals.com/oncotarget
 5. Davila JA, El-Serag HB. Racial differences in survival of 
hepatocellular carcinoma in the United States: a population-
based study. Clin Gastroenterol Hepatol. 2006; 4:104–110; 
quiz 104–105.
 6. Sloane D, Chen H, Howell C. Racial disparity in primary 
hepatocellular carcinoma: tumor stage at presentation, 
surgical treatment and survival. J Natl Med Assoc. 2006; 
98:1934–1939.
 7. Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, 
Bhuket T, Wong RJ. Race/Ethnicity-specific Disparities in 
Hepatocellular Carcinoma Stage at Diagnosis and its Impact 
on Receipt of Curative Therapies. J Clin Gastroenterol. 
2015.2016; 50:423–430.
 8. Siegel AB, McBride RB, El-Serag HB, Hershman DL, 
Brown RS, Jr., Renz JF, Emond J, Neugut AI. Racial 
disparities in utilization of liver transplantation for 
hepatocellular carcinoma in the United States, 1998–2002. 
Am J Gastroenterol. 2008; 103:120–127.
 9. Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, 
Dimick JB, Sonnenday CJ. Racial/ethnic disparities in 
access to care and survival for patients with early-stage 
hepatocellular carcinoma. Arch Surg. 2010; 145:1158–1163.
10. Ananthakrishnan AN, Saeian K. Racial differences in 
liver transplantation outcomes in the MELD era. Am J 
Gastroenterol. 2008; 103:901–910.
11. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, 
Ghafoor A, Thun M. Cancer disparities by race/ethnicity 
and socioeconomic status. CA Cancer J Clin. 2004; 
54:78–93.
12. Hoehn RS, Hanseman DJ, Wima K, Ertel AE, Paquette IM, 
Abbott DE, Shah SA. Does race affect management and 
survival in hepatocellular carcinoma in the United States? 
Surgery. 2015; 158:1244–1251.
13. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. 
Changing hepatocellular carcinoma incidence and 
liver cancer mortality rates in the United States. Am J 
Gastroenterol. 2014; 109:542–553.
14. Ha J, Yan M, Aguilar M, Bhuket T, Tana MM, Liu B, 
Gish RG, Wong RJ. Race/ethnicity-specific disparities in 
cancer incidence, burden of disease, and overall survival 
among patients with hepatocellular carcinoma in the 
United States. LID - 10.1002/cncr.30103 [doi]. (1097–0142 
(Electronic)).
15. Alawadi ZM, Phatak UR, Kao LS, Ko TC, Wray CJ. Race 
not rural residency is predictive of surgical treatment for 
hepatocellular carcinoma: Analysis of the Texas Cancer 
Registry. Journal of Surgical Oncology. 2016:84–88.
16. Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. 
Ethnic disparities and liver transplantation rates in 
hepatocellular carcinoma patients in the recent era: results 
from the Surveillance, Epidemiology, and End Results 
registry. Liver Transpl. 2014; 20:528–535.
17. Edge SB, American Joint Committee on C. AJCC cancer 
staging manual. (New York: Springer). 2010.
18. European Association For The Study Of The L, European 
Organisation For R, Treatment Of C. EASL-EORTC 
clinical practice guidelines: management of hepatocellular 
carcinoma. J Hepatol. 2012; 56:908–943.
19. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. 
Development of Hong Kong Liver Cancer staging system 
with treatment stratification for patients with hepatocellular 
carcinoma. Gastroenterology. 2014; 146:1691–1700 e1693.
20. Wang L, Wilson SE, Stewart DB, Hollenbeak CS. Marital 
status and colon cancer outcomes in US Surveillance, 
Epidemiology and End Results registries: does marriage 
affect cancer survival by gender and stage? Cancer 
Epidemiol. 2011; 35:417–422.
21. Martinez ME, Anderson K, Murphy JD, Hurley S, 
Canchola AJ, Keegan TH, Cheng I, Clarke CA, Glaser SL, 
Gomez SL. Differences in marital status and mortality 
by race/ethnicity and nativity among California cancer 
patients. Cancer. 2016; 122:1570–1578.
22. Gomez SL, Hurley S, Canchola AJ, Keegan TH, Cheng I, 
Murphy JD, Clarke CA, Glaser SL, Martinez ME. Effects 
of marital status and economic resources on survival 
after cancer: A population-based study. Cancer. 2016; 
122:1618–1625.
23. Wang XD, Qian JJ, Bai DS, Li ZN, Jiang GQ, Yao J. Marital 
status independently predicts pancreatic cancer survival in 
patients treated with surgical resection: an analysis of the 
SEER database. Oncotarget. 2016; 7:24880–24887. doi: 
10.18632/oncotarget.8467.
24. Hwang SJ, Tong MJ, Lai PP, Ko ES, Co RL, Chien D, 
Kuo G. Evaluation of hepatitis B and C viral markers: 
clinical significance in Asian and Caucasian patients with 
hepatocellular carcinoma in the United States of America. J 
Gastroenterol Hepatol. 1996; 11:949–954.
25. Prenner S, Rinella ME. Moderate Exercise for 
Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 
2016; 176:1083–1084.
26. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, 
Bozzetti F, Montalto F, Ammatuna M, Morabito A, 
Gennari L. Liver transplantation for the treatment of small 
hepatocellular carcinomas in patients with cirrhosis. N Engl 
J Med. 1996; 334:693–699.
27. Zak Y, Rhoads KF, Visser BC. Predictors of surgical 
intervention for hepatocellular carcinoma: race, 
socioeconomic status, and hospital type. Arch Surg. 2011; 
146:778–784.
28. Freeman RB. Liver transplantation for hepatocellular 
carcinoma: racial disparities? Am J Gastroenterol. 2008; 
103:128–130.
29. Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial 
and geographic disparities in the utilization of surgical 
therapy for hepatocellular carcinoma. J Gastrointest Surg. 
2007; 11:1636–1646; discussion 1646.
30. Sarpel U, Suprun M, Sofianou A, Berger Y, 
Tedjasukmana A, Sekendiz Z, Bagiella E, Schwartz ME. 
Disentangling the effects of race and socioeconomic factors 
on liver transplantation rates for hepatocellular carcinoma. 
Clin Transplant. 2016: 30:714–721.
